Here's Why You Should Retain OPKO Health Stock in Your Portfolio

Zacks10-02

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2472725115?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FOt5yoPGZDXqqqRixKRUjg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0ca166da0611a732bee917d82b962573","is_english":true,"pubTime":"2024-10-02 23:54","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2472725115","market":"us","top_or_hot":-1,"title":"Here's Why You Should Retain OPKO Health Stock in Your Portfolio","media":"Zacks","content":"<div>\n<p>OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-retain-opko-health-155400319.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's Why You Should Retain OPKO Health Stock in Your Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's Why You Should Retain OPKO Health Stock in Your Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-02 23:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/heres-why-retain-opko-health-155400319.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...</p>\n\n<a href=\"https://finance.yahoo.com/news/heres-why-retain-opko-health-155400319.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BLSP4239.USD","symbol_name":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","start_time":0,"source_url":"https://finance.yahoo.com/news/heres-why-retain-opko-health-155400319.html","article_id":"2472725115","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FOt5yoPGZDXqqqRixKRUjg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0ca166da0611a732bee917d82b962573"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472725115","pubTimestamp":1727884440,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"OPKO Health, Inc.OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE are concerns.Shares of this Zacks Rank #3  company have lost 1.3% year to date against theindustry's 9.8% growth. The S&P 500 has gained 21% in the said time frame.This renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.03 billion. It projects 44.4% growth for 2025 and expects to maintain its strong performance. In the trailing four quarters, OPKO Health surpassed earnings estimates once, matched estimates once and missed on two occasions, the average beat being 8.34%.On the second-quarter 2024 earnings call, management confirmed Rayaldee's steady performance. Our model projects the bottom line to witness a CAGR of 7.4% between 2023 and 2026, while Product revenues are expecte","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4581":"高盛持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4196":"保健护理服务","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4539":"次新股","OPK":"Opko Health","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","ATIP":"ATI Physical Therapy Inc.","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4185":"保健护理机构","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","AVAH":"Aveanna Healthcare Holdings Inc.","LU0122379950.USD":"贝莱德世界健康科学A2","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","THC":"泰尼特","LU0058720904.USD":"联博国际健康护理基金A","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4568":"美国抗疫概念","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC"},"translate_title":"这就是为什么您应该在投资组合中保留OPKO Health股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVAH":1,"THC":1,"OPK":1,"ATIP":1},"content_text":"OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE are concerns.\nShares of this Zacks Rank #3 (Hold) company have lost 1.3% year to date against the industry's 9.8% growth. The S&P 500 has gained 21% in the said time frame.\nThis renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.03 billion. It projects 44.4% growth for 2025 and expects to maintain its strong performance. In the trailing four quarters, OPKO Health surpassed earnings estimates once, matched estimates once and missed on two occasions, the average beat being 8.34%.\nImage Source: Zacks Investment Research\nFactors Favoring OPK Stock\nPotential of RAYALDEE: It has been a key driver of OPKO Health's pharmaceutical performance, leading the U.S. renal market for the past two years as the only FDA-approved therapy for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. Strong sales efforts and new evidence of its potential to improve patient outcomes drive its momentum.\nOn the second-quarter 2024 earnings call, management confirmed Rayaldee's steady performance. Our model projects the bottom line to witness a CAGR of 7.4% between 2023 and 2026, while Product revenues are expected to witness a 1.5% CAGR.\nStrategic Agreements: OPKO Health's strategic agreements boost its financial stability and growth potential. A $250 million deal with HealthCare Royalty allows OPKO to retain a significant profit share from Pfizer’s NGENLA, with the potential for $100 million in milestone payments. In March, OPKO sold its BioReference Health assets to Labcorp, focusing on oncology and urology diagnostics. Its global partnership with Pfizer for NGENLA, approved in over 50 markets, supports OPKO’s long-term performance, with both companies developing new licensed products. These agreements enhance OPKO’s position in the diagnostics and pharmaceutical markets.\nBioreference: OPKO Health’s diagnostics arm, led by BioReference, is key to its performance, serving nine million customers in 2023. BioReference offers extensive testing, including the 4Kscore prostate cancer test, and services in molecular diagnostics and women’s health. In second-quarter 2024, OPKO expanded its oncology offerings with new IHC stains and advanced testing platforms. It plans to launch the MDX2001 immune modulator in clinical trials next year. Diagnostics revenues grew 1.9%, driven by oncology, reinforcing OPKO’s growth in diagnostics.\nDownsides\nStiff Competition: OPKO Health faces significant competition in both its pharmaceutical and diagnostics businesses. Major pharmaceutical, diagnostic companies and research institutions have much larger financial and operational resources, enabling them to invest heavily in R&D and marketing, often over a broader revenue base. Competitors like Quest Diagnostics and Laboratory Corporation of America dominate the diagnostics sector, making it challenging for OPKO to compete. This disparity in resources and reach may limit OPKO's ability to innovate and scale as effectively as its larger rivals, potentially hindering its growth and market share.\nOverdependence on RAYALDEE: OPKO Health's financial success depends heavily on the commercialization of Rayaldee, its only approved pharmaceutical product in the United States. Failure to effectively market Rayaldee could severely impact the company's revenues, profitability and overall business operations. Additionally, Rayaldee's market reputation, safety and perceived efficacy are crucial. Any negative publicity, safety concerns, or rumors about the product could significantly harm OPKO's business, undermining the product's acceptance and damaging the company's financial outlook.\nEstimate Trend\nOPKO Health is witnessing a positive estimate revision trend for 2024. In the past 90 days, the Zacks Consensus Estimate for its loss has narrowed from 36 cents to 29 cents per share.\nThe Zacks Consensus Estimate for the company’s third-quarter 2024 revenues and loss per share is pegged at $181.3 million and 10 cents, respectively. The revenue estimate suggests 1.5% growth from the year-ago quarter’s reported number.\n\nOPKO Health, Inc. Price\n\nOPKO Health, Inc. price | OPKO Health, Inc. Quote\n\nKey Picks\nSome better-ranked stocks in the broader medical space are Tenet HealthCare (THC), ATI Physical Therapy (ATIP) and Aveanna Healthcare AVAH. While Tenet HealthCare sports a Zacks Rank #1 (Strong Buy), ATI Physical Therapy and Aveanna Healthcare carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nTenet HealthCare has an estimated long-term growth rate of 18.3%. THC's earnings surpassed estimates in each of the trailing four quarters, with the average being 58.5%.\nTenet HealthCare has gained 119.9% compared with the industry's 48.6% growth year to date.\nATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.25%.\nATIP's shares have gained 5.5% year to date compared with the industry’s 18.6% growth.\nAveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.\nAVAH's shares have surged 104.5% year to date compared with the industry’s 15.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nTenet Healthcare Corporation (THC) : Free Stock Analysis Report\nOPKO Health, Inc. (OPK) : Free Stock Analysis Report\nAveanna Healthcare Holdings Inc. (AVAH) : Free Stock Analysis Report\nATI Physical Therapy, Inc. (ATIP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2472725115"}